A Phase 2 interventional study of D/C/F/TAF and DRV in Acquired Immunodeficiency Syndrome and HIV Infections, sponsored by Gilead Sciences. Completed at 44 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-04-11.
Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing tenofovir alafenamide in Acquired Immunodeficiency Syndrome — 1 open to participants now, 2 under way, 1 of them phase 3. tenofovir alafenamide · Acquired Immunodeficiency Syndrome.
Among the 21 studies testing tenofovir alafenamide in Acquired Immunodeficiency Syndrome, this one is the 6th largest by enrollment, is the only one that started in 2012, is one of 3 in phase 2, and was the 2nd registered.
3,037 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.
Browse Acquired Immunodeficiency Syndrome studies →1 of the 21 studies testing tenofovir alafenamide in Acquired Immunodeficiency Syndrome is open now, in 1 country. Recruiting first, the newest first:
CAN Community Health · Sites in United States
Ages 18+
By country, each count listing its studies:
tenofovir alafenamide: first FDA approval 2015 (GENVOYA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 198 Acquired Immunodeficiency Syndrome studies recruiting now, 118 (60%) set no upper age limit and 67 (34%) stop at 75 or younger; 43 take children under 18; 68 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 5 · Phase 3 8 · Phase 4 5
First in 2011; this study’s year is marked. 1 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 153 is above the median of 96 across 2,253 interventional studies indexed under Acquired Immunodeficiency Syndrome.
Median enrollment 80 across the 21 interventional studies. Of the 15 that completed or were terminated, 10 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 21 have an industry lead sponsor. The 10 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
35 studies in Acquired Immunodeficiency Syndrome by Gilead Sciences: none open now, 1 under way, 1 of them phase 3. Of 34 finished, 19 (56%) have results posted.
Among the 35 studies in Acquired Immunodeficiency Syndrome by Gilead Sciences, this one is the 14th largest by enrollment of the 34 interventional ones that give a count, is one of 5 that started in 2012, is one of 7 in phase 2, and was the 25th registered.
Gilead Sciences’s Acquired Immunodeficiency Syndrome studies by the year they started, since 2003.
1 of the studies testing tenofovir alafenamide in Acquired Immunodeficiency Syndrome that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07476339CAN Community HealthREINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidE | 2027-06-17 |
Add it to your calendar (.ics) → With an account.
Among the 21 studies testing tenofovir alafenamide in Acquired Immunodeficiency Syndrome, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Gilead Sciences’s 35 in Acquired Immunodeficiency Syndrome:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is to evaluate the safety and efficacy darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed dose combination (FDC) tablet versus darunavir (DRV)+cobicistat (COBI)+emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) in HIV-1 infected, antiretroviral treatment-naive adults as determined by the achievement of HIV-1 RNA \< 50 copies/mL at Week 24.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
D/C/F/TAF FDC tablet plus DRV placebo plus COBI placebo plus FTC/TDF placebo
Drug: D/C/F/TAF · Drug: DRV Placebo · Drug: COBI Placebo · Drug: FTC/TDF Placebo
DRV tablet plus COBI tablet plus FTC/TDF 200/300 mg FDC tablet plus D/C/F/TAF placebo
Drug: DRV · Drug: COBI · Drug: FTC/TDF · Drug: D/C/F/TAF Placebo
Drug page: Tenofovir alafenamide
DRV 800 mg/COBI 150 mg/FTC 200 mg/TAF 10 mg FDC tablet administered orally once daily
DRV 800 mg (2 × 400 mg tablets) administered orally once daily
Also known as: Prezista®
COBI 150 mg tablet administered orally once daily
Also known as: Tybost®, GS-9350
FTC 200 mg/TDF 300 mg FDC tablet administered orally once daily
Also known as: Truvada®
D/C/F/TAF placebo tablet administered orally once daily
DRV placebo tablet administered orally once daily
COBI placebo tablet administered orally once daily
FTC/TDF placebo tablet administered orally once daily
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24
The snapshot algorithm was used which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 24
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48
The snapshot algorithm was used which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 48
Change From Baseline in HIV-1 RNA at Week 24
Time frame: Baseline; Week 24
Change From Baseline in HIV-1 RNA at Week 48
Time frame: Baseline; Week 48
Change From Baseline in CD4+ Cell Count at Week 24
Time frame: Baseline; Week 24
Change From Baseline in CD4+ Cell Count at Week 48
Time frame: Baseline; Week 48
Participants were enrolled at study sites in the United States (including Puerto Rico). The first participant was screened on 16 April 2012. The last study visit occurred on 19 February 2014.
| Milestone | D/C/F/TAF | DRV+COBI+FTC/TDF |
|---|---|---|
| Started | 103 | 50 |
| Completed | 83 | 42 |
| Not completed | 20 | 8 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Lost to follow-up | 12 | 4 |
| Withdrew: Investigator's discretion | 2 | 1 |
| Withdrew: Participant noncompliance | 2 | 0 |
| Withdrew: Withdrew consent | 4 | 2 |
The snapshot algorithm was used which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | D/C/F/TAF | DRV+COBI+FTC/TDF |
|---|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 | 74.8 | 74.0 |
The snapshot algorithm was used which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | D/C/F/TAF | DRV+COBI+FTC/TDF |
|---|---|---|
| Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 | 76.7 | 84.0 |
| log10 copies/mL | D/C/F/TAF | DRV+COBI+FTC/TDF |
|---|---|---|
| Change From Baseline in HIV-1 RNA at Week 24 | -3.20 ± 0.653 | -3.18 ± 0.416 |
| log10 copies/mL | D/C/F/TAF | DRV+COBI+FTC/TDF |
|---|---|---|
| Change From Baseline in HIV-1 RNA at Week 48 | -3.27 ± 0.668 | -3.26 ± 0.521 |
| cells/µL | D/C/F/TAF | DRV+COBI+FTC/TDF |
|---|---|---|
| Change From Baseline in CD4+ Cell Count at Week 24 | 186 ± 137.9 | 139 ± 185.8 |
| cells/µL | D/C/F/TAF | DRV+COBI+FTC/TDF |
|---|---|---|
| Change From Baseline in CD4+ Cell Count at Week 48 | 231 ± 141.9 | 212 ± 151.5 |
Collected over Baseline through end of study drug treatment (average exposure: D/C/F/TAF group = 61.7 weeks; DRV+COBI+FTC/TDF group = 66.1 weeks) plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| D/C/F/TAF | — | 5/103 (4.9%) | 77/103 (74.8%) |
| DRV+COBI+FTC/TDF | — | 2/50 (4%) | 40/50 (80%) |
| Event | D/C/F/TAF | DRV+COBI+FTC/TDF |
|---|---|---|
| BronchitisInfections and infestations | 0/103 | 1/50 |
| Bronchitis viralInfections and infestations | 0/103 | 1/50 |
| PneumoniaInfections and infestations | 0/103 | 1/50 |
| Renal tubular disorderRenal and urinary disorders | 0/103 | 1/50 |
| Diarrhoea haemorrhagicGastrointestinal disorders | 1/103 | 0/50 |
| HypersensitivityImmune system disorders | 1/103 | 0/50 |
| CellulitisInfections and infestations | 1/103 | 0/50 |
| Psychotic disorderPsychiatric disorders | 1/103 | 0/50 |
| Substance abusePsychiatric disorders | 1/103 | 0/50 |
| Event | D/C/F/TAF | DRV+COBI+FTC/TDF |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 22/103 | 13/50 |
| FatigueGeneral disorders | 14/103 | 9/50 |
| Upper respiratory tract infectionInfections and infestations | 16/103 | 7/50 |
| NauseaGastrointestinal disorders | 13/103 | 5/50 |
| FlatulenceGastrointestinal disorders | 5/103 | 6/50 |
| RashSkin and subcutaneous tissue disorders | 12/103 | 4/50 |
| VomitingGastrointestinal disorders | 4/103 | 5/50 |
| Vitamin D deficiencyMetabolism and nutrition disorders | 2/103 | 5/50 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 8/103 | 5/50 |
| BronchitisInfections and infestations | 9/103 | 2/50 |
Safety Analysis Set: participants who were randomized and received at least one dose of study drug
| Age, Continuous(years) | D/C/F/TAF | DRV+COBI+FTC/TDF | Total |
|---|---|---|---|
| Mean | 35 ± 11.3 | 37 ± 10.9 | 35 ± 11.2 |
| Sex: Female, Male(Participants) | D/C/F/TAF | DRV+COBI+FTC/TDF | Total |
|---|---|---|---|
| Female | 8 | 3 | 11 |
| Male | 95 | 47 | 142 |
| Ethnicity (NIH/OMB)(Participants) | D/C/F/TAF | DRV+COBI+FTC/TDF | Total |
|---|---|---|---|
| Hispanic or Latino | 23 | 9 | 32 |
| Not Hispanic or Latino | 80 | 41 | 121 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(participants) | D/C/F/TAF | DRV+COBI+FTC/TDF | Total |
|---|---|---|---|
| White | 62 | 30 | 92 |
| Black or African American | 36 | 17 | 53 |
| Asian | 2 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 1 | 1 | 2 |
| Other | 2 | 1 | 3 |
| Region of Enrollment(participants) | D/C/F/TAF | DRV+COBI+FTC/TDF | Total |
|---|---|---|---|
| United States | 103 | 50 | 153 |
| HIV-1 RNA(log10 copies/mL) | D/C/F/TAF | DRV+COBI+FTC/TDF | Total |
|---|---|---|---|
| Mean | 4.70 ± 0.516 | 4.65 ± 0.514 | 4.68 ± 0.515 |
| HIV-1 RNA Category(participants) | D/C/F/TAF | DRV+COBI+FTC/TDF | Total |
|---|---|---|---|
| ≤ 100,000 copies/mL | 80 | 43 | 123 |
| > 100,000 to ≤ 400,000 copies/mL | 17 | 5 | 22 |
| > 400,000 copies/mL | 6 | 2 | 8 |
| CD4 Cell Count(cells/µL) | D/C/F/TAF | DRV+COBI+FTC/TDF | Total |
|---|---|---|---|
| Mean | 395 ± 169.3 | 464 ± 261.6 | 417 ± 205.7 |
1 further baseline measures are reported on the registry.
The record gives a start of Apr 2012, a primary completion of Jan 2013 and a completion of Feb 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2016, 3 years 3 months after primary completion. A results delay was requested in Nov 2013.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tenofovir alafenamide
Acquired Immunodeficiency Syndrome →